Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06277804
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2024-02-07
Brief Title:
A Phase I Study of LTC004 Combin With FC in Patients With AdvancedMetastatic Malignancies Tumor
Sponsor:
Letolab
Organization:
Letolab
Study Overview
Official Title:
A Phase I Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of LTC004 in Combination With Cyclophosphamide and Fludarabine in Patients With Advanced or Metastatic Malignancies Tumor
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a multicenter open PHASE I study of LTC004 in Combination With Cyclophosphamide and Fludarabine in Patients With AdvancedMetastatic Malignancies Tumor the study design consisting of 2 phases Phase Ia Phase Ia dose escalation and Phase Ib Phase Ib expansion The objective of this study was to evaluate combination safety tolerability pharmacokineticpharmacodynamics characteristics and initial efficacy in advanced malignant tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None